Unraveling the etiology of congenital heart defects – The role of maternal genetics and cardiovascular disease as a risk factor
This project aims to investigate how maternal genetics and cardiovascular health influence the risk of congenital heart defects in offspring, utilizing extensive Finnish health data and biomarker analysis.
Projectdetails
Introduction
One in a hundred infants is born with a congenital heart defect (CHD). Both genetic and environmental risk factors, such as maternal diabetes and obesity, are known to cause CHD; however, little is known about the disease mechanisms behind these risks. CHD can occur as an element of a syndrome, in conjunction with other anomalies, or as an isolated defect.
Hypothesis
I propose that there is an etiologically distinct environmental CHD subgroup, where, in addition to the child's genes, maternal genetics and gene expression play a major role in disease development. Moreover, I propose that in these cases, the genetic risk profile predisposes the woman to both having offspring with CHD and having early onset atherosclerotic disease.
Objectives
My objective is to study how maternal genetics and maternal cardiovascular morbidity as an environmental risk contribute to the risk of having offspring with CHD. In addition, the multifactorial aetiology in terms of the presence of both risk factors will be studied using a unique dataset available only in Finland.
Methodology
Three different substudies will be conducted:
- Finnish national registers gathering health-related information of all Finns from birth to death will be used to determine the presence of atherosclerosis and related traits, such as hypertension and coronary artery disease, in mothers who have offspring with CHD compared to those without (total N = 1 million).
- Maternal genetic risk loci for having CHD in the offspring will be sought in the FinnGen study (total N = 0.5 million).
- Maternal 1st trimester serum samples from pregnancies with and without CHD will be analyzed to identify CHD associated biomarkers (total N = 3200).
Expected Outcomes
The study results will provide important information on how the combination of maternal genetic and environmental risk factors contribute to cardiac developmental defects during early pregnancy and offer new insights for future research on the cellular and molecular mechanisms of cardiac development.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 1.495.845 |
Totale projectbegroting | € 1.495.845 |
Tijdlijn
Startdatum | 1-7-2023 |
Einddatum | 30-6-2028 |
Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- HELSINGIN YLIOPISTOpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Impact of the embryonic obesogenic environment on programming of cardiovascular diseases across the life courseOBESE-EMBRYO aims to improve cardiovascular health in future generations by targeting the embryonic obesogenic environment in overweight and obese parents-to-be through innovative, evidence-based interventions. | ERC Starting... | € 1.499.998 | 2025 | Details |
Mental illness, substance use, and cardiovascular disease: Unravelling causal relationshipsThis project aims to clarify the bidirectional relationships between serious mental illness and its comorbidities using innovative epidemiological methods to enhance prevention and treatment strategies. | ERC Starting... | € 1.500.000 | 2023 | Details |
Single cEll guided polygeniC Risk prEdicTion of ASCVDThis project aims to develop innovative polygenic risk models for atherosclerotic cardiovascular disease by leveraging genetic data and mechanistic insights to improve risk prediction and prevention. | ERC Consolid... | € 2.000.000 | 2024 | Details |
Dynamic engIneered heart tiSsue to Study intEr-individual susCeptibily and improve Treatment of Heart FailureDISSECT-HF aims to engineer heart tissue from patient-specific stem cells to uncover common mechanisms of heart failure across different etiologies and improve treatment strategies. | ERC Consolid... | € 1.998.775 | 2022 | Details |
Social Inequalities in the Risk and Aftermath of MiscarriageThis project aims to comprehensively analyze social inequalities in miscarriage and its health impacts using rich longitudinal data from Finland, France, and the UK to inform better reproductive health policies. | ERC Starting... | € 1.256.107 | 2024 | Details |
Impact of the embryonic obesogenic environment on programming of cardiovascular diseases across the life course
OBESE-EMBRYO aims to improve cardiovascular health in future generations by targeting the embryonic obesogenic environment in overweight and obese parents-to-be through innovative, evidence-based interventions.
Mental illness, substance use, and cardiovascular disease: Unravelling causal relationships
This project aims to clarify the bidirectional relationships between serious mental illness and its comorbidities using innovative epidemiological methods to enhance prevention and treatment strategies.
Single cEll guided polygeniC Risk prEdicTion of ASCVD
This project aims to develop innovative polygenic risk models for atherosclerotic cardiovascular disease by leveraging genetic data and mechanistic insights to improve risk prediction and prevention.
Dynamic engIneered heart tiSsue to Study intEr-individual susCeptibily and improve Treatment of Heart Failure
DISSECT-HF aims to engineer heart tissue from patient-specific stem cells to uncover common mechanisms of heart failure across different etiologies and improve treatment strategies.
Social Inequalities in the Risk and Aftermath of Miscarriage
This project aims to comprehensively analyze social inequalities in miscarriage and its health impacts using rich longitudinal data from Finland, France, and the UK to inform better reproductive health policies.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Cardiogenomics meets Artificial Intelligence: a step forward in arrhythmogenic cardiomyopathy diagnosis and treatmentThe project aims to integrate genomics, proteomics, and structural analyses to clarify genotype-phenotype relationships in arrhythmogenic cardiomyopathy, paving the way for novel therapies. | EIC Pathfinder | € 3.740.868 | 2023 | Details |
A Multi-Omics Approach for Novel Drug Targets, Biomarkers and Risk Algorithms for Myocardial InfarctionTargetMI aims to rapidly discover novel drug targets and biomarkers for myocardial infarction using a high-throughput multi-omic approach on 1000 samples, enhancing clinical risk prediction and translation. | EIC Pathfinder | € 3.999.840 | 2023 | Details |
MultiomIcs based Risk stratification of Atherosclerotic CardiovascuLar disEaseThe MIRACLE project aims to develop advanced multiomics-based risk prediction models for atherosclerotic cardiovascular disease by integrating genetic data and biomarkers for improved early diagnosis and treatment. | EIC Pathfinder | € 4.000.000 | 2023 | Details |
Enabling advances in diagnosis, patient stratification and treatment for dilated cardiomyopathy patients and families.The DCM-NEXT consortium aims to enhance genetic testing and develop novel therapies for dilated cardiomyopathy by leveraging extensive clinical and omics data from 11,750 patients. | EIC Pathfinder | € 4.137.668 | 2023 | Details |
Cardiogenomics meets Artificial Intelligence: a step forward in arrhythmogenic cardiomyopathy diagnosis and treatment
The project aims to integrate genomics, proteomics, and structural analyses to clarify genotype-phenotype relationships in arrhythmogenic cardiomyopathy, paving the way for novel therapies.
A Multi-Omics Approach for Novel Drug Targets, Biomarkers and Risk Algorithms for Myocardial Infarction
TargetMI aims to rapidly discover novel drug targets and biomarkers for myocardial infarction using a high-throughput multi-omic approach on 1000 samples, enhancing clinical risk prediction and translation.
MultiomIcs based Risk stratification of Atherosclerotic CardiovascuLar disEase
The MIRACLE project aims to develop advanced multiomics-based risk prediction models for atherosclerotic cardiovascular disease by integrating genetic data and biomarkers for improved early diagnosis and treatment.
Enabling advances in diagnosis, patient stratification and treatment for dilated cardiomyopathy patients and families.
The DCM-NEXT consortium aims to enhance genetic testing and develop novel therapies for dilated cardiomyopathy by leveraging extensive clinical and omics data from 11,750 patients.